

RESEARCH ARTICLE

The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series

Ravi Mehta^{1,2}*, Cristiane Nascimento Soares³, Raquel Medialdea-Carrera^{1,2}, Mark Ellul^{1,2,4}, Marcus Tullius Teixeira da Silva^{5,6}, Anna Rosala-Hallas⁷, Marcia Rodrigues Jardim⁸, Girvan Burnside⁷, Luciana Pamplona⁹, Maneesh Bhojak⁴, Radhika Manohar⁴, Gabriel Amorelli Medeiros da Silva³, Marcus Vinicius Adriano¹⁰, Patricia Brasil¹¹, Rita Maria Ribeiro Nogueira¹², Carolina Cardoso Dos Santos¹², Lance Turtle^{1,2,4}, Patricia Carvalho de Sequeira¹², David W. Brown^{13,14}, Michael J. Griffiths^{1,2,15}, Ana Maria Bispo de Filippis¹², Tom Solomon^{1,2,4*}



OPEN ACCESS

Citation: Mehta R, Soares CN, Medialdea-Carrera R, Ellul M, da Silva MTT, Rosala-Hallas A, et al. (2018) The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series. *PLoS Negl Trop Dis* 12(2): e0006212. <https://doi.org/10.1371/journal.pntd.0006212>

Editor: David W. C. Beasley, University of Texas Medical Branch, UNITED STATES

Received: October 5, 2017

Accepted: January 4, 2018

Published: February 12, 2018

Copyright: © 2018 Mehta et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the United Kingdom Medical Research Council (<https://www.mrc.ac.uk/>, Grant number MC_PC_15096); the National Institute for Health Research Health Protection Research Unit (NIHR HPRU, <http://www.hpruezi.nihr.ac.uk/>) in Emerging and Zoonotic Infections at the University of Liverpool,

1 National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, United Kingdom, **2** Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom, **3** Department of Neurology, Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil, **4** Department of Neurology, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom, **5** Laboratório de Pesquisa em Neuroinfecção, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil, **6** Department of Neurology, Hospital de Clínicas de Niterói, Niterói, Brazil, **7** Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom, **8** Department of Neurology, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, **9** Department of Neurology, Hospital Geral de Bonsucesso, Rio de Janeiro, Brazil, **10** Department of Neurology, Hospital Barra D'or, Rio de Janeiro, Brazil, **11** Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil, **12** Flavivirus Reference Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil, **13** Influenza Reference Laboratory, Oswaldo Cruz Institute, Rio de Janeiro, Brazil, **14** Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom, **15** Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom

* These authors contributed equally to this work.
* tsolomon@liv.ac.uk (TS); Ravi.mehta@liverpool.ac.uk (RM)

Abstract

Background

During 2015–16 Brazil experienced the largest epidemic of Zika virus ever reported. This arthropod-borne virus (arbovirus) has been linked to Guillain-Barré syndrome (GBS) in adults but other neurological associations are uncertain. Chikungunya virus has caused outbreaks in Brazil since 2014 but associated neurological disease has rarely been reported here. We investigated adults with acute neurological disorders for Zika, chikungunya and dengue, another arbovirus circulating in Brazil.

Methods

We studied adults who had developed a new neurological condition following suspected Zika virus infection between 1st November 2015 and 1st June 2016. Cerebrospinal fluid (CSF), serum, and urine were tested for evidence of Zika, chikungunya, and dengue viruses.

in partnership with Public Health England (PHE) and Liverpool School of Tropical Medicine (LSTM); and the European Union's Horizon 2020 research and innovation program under grant agreement No. 734584 (<https://ec.europa.eu/programmes/horizon2020/>). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Results

Of 35 patients studied, 22 had evidence of recent arboviral infection. Twelve had positive PCR or IgM for Zika, five of whom also had evidence for chikungunya, three for dengue, and one for all three viruses. Five of them presented with GBS; seven had presentations other than GBS, including meningoencephalitis, myelitis, radiculitis or combinations of these syndromes. Additionally, ten patients positive for chikungunya virus, two of whom also had evidence for dengue virus, presented with a similar range of neurological conditions.

Conclusions

Zika virus is associated with a wide range of neurological manifestations, including central nervous system disease. Chikungunya virus appears to have an equally important association with neurological disease in Brazil, and many patients had dual infection. To understand fully the burden of Zika we must look beyond GBS, and also investigate for other co-circulating arboviruses, particularly chikungunya.

Author summary

During 2015–16, Brazil experienced the largest outbreak of the mosquito-borne Zika virus ever reported and saw a subsequent increase in cases of Guillain-Barré syndrome (GBS), a disorder of the peripheral nervous system (nerves outside the brain and spinal cord) that can result in paralysis and sometimes death. In this assessment of adults presenting with suspected Zika virus-associated neurological disease in Rio de Janeiro, Brazil, we add to the growing body of evidence linking Zika to a wider range of neurological disease, including disease of the central nervous system (brain and spinal cord). We also show that many patients initially thought to have neurological disease associated with Zika virus were in fact infected with chikungunya virus, another arthropod-borne virus (arbovirus) that is also associated with a wide range of neurological disease. Importantly, many patients had evidence of infection with more than one virus. We discuss the challenges in diagnosing the infections and how different body fluid samples can be used to help facilitate this. Our results suggest that clinicians and public health officials must look beyond GBS if we are to understand fully the disease burden of Zika virus. In addition, we highlight the need to investigate patients with acute neurological syndromes for other co-circulating arboviruses, particularly chikungunya.

Introduction

Zika virus is an arthropod-borne virus (arbovirus) first isolated in Uganda in 1947, which spread to cause large outbreaks in Micronesia in 2007, French Polynesia in 2014 and Latin America from 2015.[1] By December 2015, it had caused an estimated 0.4–1.3 million cases in Brazil alone.[2] Like the related dengue viruses, Zika is a flavivirus (genus *Flavivirus*, family *Flaviviridae*) that causes a fever-arthralgia-rash syndrome and is transmitted principally by *Aedes* mosquitoes. An apparent association between Zika virus and an increase in severe congenital disease and other neurological disorders, particularly Guillain-Barré syndrome (GBS), [3–6] prompted the World Health Organisation to declare Zika virus a public health emergency of international concern in February 2016.[7]

A carefully conducted case-control study of the French Polynesian outbreak showed an association between Zika virus infection and GBS,[4] although prior dengue exposure made interpretation of the virology results challenging because of serological cross reactivity between flaviviruses.[8] Dengue, like other flaviviruses including Japanese encephalitis and West Nile viruses, can also cause both peripheral and central nervous system (CNS) disease.[9] Secondary dengue infections are associated with more severe dengue disease, and some have postulated that prior dengue may predispose to more severe Zika infection. More recently, a study from Colombia has shown a strong temporal association between GBS and Zika virus, with viral RNA detected in samples from 17 patients.[5] A few case reports have described Zika virus-associated myelitis,[10] encephalitis,[11, 12] meningoencephalitis,[13] acute disseminated encephalomyelitis,[14] Miller-Fisher syndrome,[15] and myasthenia gravis,[16] suggesting that the spectrum of neurological disease may be broader than initially thought. A preliminary epidemiological report from the French Polynesian outbreak indicated a possible increase in other neurological manifestations associated with Zika virus, but gave few details.[17]

Chikungunya is another arbovirus also identified in Africa in the 1950s that has spread to cause epidemics in the tropics in recent years.[18] It was first reported in Latin America in 2013 and has caused large outbreaks in Brazil in the last two years, with over 260,000 suspected cases in 2016.[19] Like Zika and dengue viruses, it is transmitted by *Aedes* mosquitoes and leads to a fever-arthralgia-rash syndrome; it also occasionally presents with neurological disease, including GBS, encephalitis and myelitis,[20] although there are few such reports from South America.[21] Because chikungunya is an alphavirus (genus *Alphavirus*, family *Togaviridae*) there is no serological cross reactivity with the flaviviruses, making diagnosis more straightforward. Although chikungunya virus co-circulates in many Zika-affected areas, including Colombia and Brazil, and can cause neurological disease, its role has not been assessed.

To assess the spectrum of neurological disease associated with Zika virus, we studied adults in Rio de Janeiro with acute neurological syndromes following suspected Zika virus infection. Given their similarities and co-circulation, we also investigated for chikungunya and dengue viruses.

Methods

We studied patients who had developed a new neurological condition associated with suspected Zika virus infection, whose samples had been submitted to the Flavivirus Reference Laboratory of the Instituto Oswaldo Cruz (Fiocruz), Rio de Janeiro.

Ethics statement

The study protocol was approved by the Comitê de Ética em Pesquisa do Instituto Nacional de Infectologia Evandro Chagas (reference 59254116.0.1001.5262). Patient-identifying data was anonymised.

Study population

We studied patients admitted in 11 hospitals (appendix) in Rio de Janeiro from 1st November 2015 to 1st June 2016, who had presented with an acute neurological condition associated with a suspected Zika virus infection, as identified by fever, arthralgia or rash illness in the preceding three months. In this evolving epidemic situation we used three approaches to identify patients: using the laboratory database, we retrospectively identified 29 patients who had had either cerebrospinal fluid (CSF) regardless of indication, or serum and/or urine in the context

of neurological disease, sent to the laboratory for Zika virus diagnostics; additionally, clinicians from our study hospitals identified six further patients, whose CSF sample was not on the database and whose serum and/or urine request forms did not have an indication (Fig 1). Patients under the age of 12 months were excluded.

Clinical information was obtained from case notes and discussion with the patients' clinicians and documented on standardised case report forms by a member of the study team. The information obtained included demographics, past medical history, admission history, examination, investigations, diagnosis, and management. Investigations included brain and spine imaging for patients with suspected central nervous system infection, and nerve conduction studies with or without electromyography for those with peripheral disease. Nerve conduction study results were reviewed by an independent expert neurophysiologist to ensure consistency. The Brighton criteria were used to indicate the level of certainty for diagnosing GBS and similar criteria were applied for radiculitis, encephalitis, myelitis, and meningitis (appendix). We determined whether patients had peripheral nervous system disease (GBS, radiculitis), CNS disease (encephalitis, myelitis, meningitis) or both.

Laboratory testing

CSF, serum, and urine samples were tested for evidence of Zika, chikungunya, and dengue virus infection at the Fiocruz Flavivirus Laboratory. We considered detection of viral RNA and/or IgM-specific antibody in the CSF as evidence of recent CNS infection as previously; [22] IgM antibody in the serum, or RNA in the serum or urine was taken as evidence of systemic infection.

An expanded protocol based on the interim recommendations from the WHO for laboratory testing for Zika virus was followed:[23] RNA was extracted from 140µl of CSF, serum, and urine samples and eluted in 50µl using the Qiaamp Mini Elute Virus Spin Kit from Qiagen (Brazil). The CSF, serum, and urine samples were tested by qRT-PCR for detection of Zika, chikungunya, and dengue virus RNA as described previously.[24] Serum IgM and IgG antibodies to Zika virus NS1 antigen and serum and CSF IgM and IgG antibodies to chikungunya virus were measured using commercial ELISAs (Euroimmun, Luebeck, Germany), according to the manufacturer's protocol.[25–27] CSF IgM antibodies to Zika virus were measured using a recommended capture ELISA based on the US Centers for Disease Control and Prevention (CDC) emergency use authorization protocol (CDC Fort Collins, CO, USA).[28] Serum and CSF IgM and IgG antibodies to dengue virus were measured using commercial ELISAs (Panbio, Brazil). For serum samples with sufficient volume remaining, anti-ganglioside antibodies, which are associated with GBS and other autoimmune neuropathies, were tested by ELISA (Bühlmann-Gangliocombi, Schönenbuch, Switzerland) following the manufacturer's instructions.

Statistical analysis

The median time from illness onset to the development of neurological symptoms was compared for those with CNS and peripheral nervous system disease, and for those with or without CNS Zika virus infection, using the Wilcoxon-Mann-Whitney U-test.

Results

We identified 35 patients with new neurological disease associated with a suspected Zika virus infection. Evidence for recent arbovirus infection was found in 22 (63%) of them. Table 1 and Fig 2 show the virological diagnosis for each patient, taking into account any potential serological cross-reactivity between flaviviruses.




Fig 1. Study population of patients with neurological disease associated with suspected Zika virus infection. *These patients did not appear in the laboratory database search because their CSF sample was not recorded on the database and no clinical information was included in request forms for serum and/or urine. They were identified by the clinicians who had previously managed their care in our study hospitals.

<https://doi.org/10.1371/journal.pntd.0006212.g001>

Twelve (34%) had evidence of Zika virus infection. Three (9%) with evidence of Zika virus infection alone presented with GBS (two patients) or encephalitis (one). Nine (26%) with evidence of Zika also had evidence for another arbovirus; five with chikungunya, three with dengue, one with both chikungunya and dengue. Three of them presented with GBS, including one with the facial diplegia and paraesthesia variant, and six had CNS infection, predominantly encephalitis and/or myelitis. Ten patients (29%) negative for Zika had evidence for another arboviral infection; eight with chikungunya and two with chikungunya and dengue. Two of these presented with GBS and eight with CNS disease.

The remaining 13 patients (37%), with no evidence of a recent Zika, chikungunya, or dengue virus infection, presented with GBS (six patients) or CNS disease (seven). Their diagnoses are given in the appendix, but they are not considered further here.

Clinical features

All 22 patients with evidence of recent arbovirus infection were Brazilian nationals with no recent travel history, from 18 different districts of Rio de Janeiro. The median (range) age was 51.5 (17–84) years. The male:female ratio was 1:1. Their individual clinical features are summarised in [Table 2](#) and a detailed example of a clinical case, patient 9, is described in [Box 1](#).

The seven patients with GBS all had a preceding febrile and/or rash syndrome, which was a median (range) 12 (5–41) days before the neurological presentation; there was no statistically significant difference in prodrome length between those with and without CNS Zika infection. The presentations for six patients were similar—typically paraesthesia (five patients) with a rapidly ascending symmetrical flaccid paralysis, involving all four limbs in five patients, or the legs only in one (patient 5). Another (patient 4) presented with a GBS variant, with bilateral lower motor neuron facial nerve palsies and paraesthesia in all four limbs.

Table 1. Virological evidence for Zika, chikungunya and/or dengue virus infection in 22 patients presenting with acute neurological disease, ordered by date of admission.

| Patient | Zika | | | | | Chikungunya | | | | | Dengue | | | | | Other CSF investigations | Virological Diagnosis |
|---------|---------|---------|-----------|-----------|-----------|-------------|---------|-----------|-----------|-----------|---------|---------|-----------|-----------|-----------|-----------------------------------|---|
| | CSF PCR | CSF IgM | Serum PCR | Serum IgM | Urine PCR | CSF PCR | CSF IgM | Serum PCR | Serum IgM | Urine PCR | CSF PCR | CSF IgM | Serum PCR | Serum IgM | Urine PCR | | |
| 1* | - | + | - | - | + | - | - | - | - | - | - | + | - | + | - | Neg: MCS, HSV, VDRL, CRAG | Zika-CNS +/- Dengue-CNS † |
| 2 | - | + | - | - | - | - | - | - | + | - | - | + | - | + | - | na | Zika-CNS or Dengue-CNS or both, Chik-Syst |
| 3 | - | + | + | - | + | - | - | - | - | - | - | - | - | + | - | Neg: HSV | Zika-CNS +/- Dengue-Syst † |
| 4 | + | + | - | - | na | + | - | + | - | na | - | - | - | - | na | Neg: MCS | Zika/Chik-CNS |
| 5 | - | + | - | - | + | - | - | - | - | - | - | - | - | - | - | Neg: MCS, VDRL | Zika-CNS |
| 6 | na | na | - | - | - | na | na | - | + | - | na | na | - | + | - | Neg: MCS, VDRL | Chik/Dengue-Syst |
| 7 | - | + | - | + | - | - | - | - | - | - | - | - | - | + | - | na | Zika-CNS or Dengue-Syst or both |
| 8 | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | Neg: MCS | Chik-CNS |
| 9 | - | + | na | na | na | + | + | na | na | na | - | - | na | na | na | Neg: HSV | Zika/Chik-CNS |
| 10 | - | + | - | + | + | - | - | - | - | - | - | na | - | - | - | Neg: MCS | Zika-CNS |
| 11 | - | - | - | - | - | + | + | - | + | + | - | - | - | - | - | Neg: MCS, VDRL | Chik-CNS |
| 12 | - | - | na | na | - | + | + | na | na | - | - | - | na | na | - | na | Chik-CNS |
| 13 | - | - | - | - | - | + | - | + | + | - | - | - | - | - | - | Neg: MCS, VDRL, CRAG, CMV/VZV/HSV | Chik-CNS |
| 14 | - | - | na | na | na | + | - | na | na | na | - | - | na | na | na | na | Chik-CNS |
| 15 | - | - | na | na | na | + | - | na | na | na | - | - | na | na | na | Neg: HSV | Chik-CNS |
| 16 | + | + | na | na | - | + | + | na | na | - | - | - | na | na | - | na | Zika/Chik-CNS |
| 17 | na | na | - | - | + | na | na | + | - | - | na | na | - | - | - | Pos: VDRL | Zika/Chik-Syst |
| 18 | - | - | na | na | + | + | + | na | na | - | - | - | na | na | - | Neg: HSV | Chik-CNS, Zika-Syst |
| 19 | - | - | - | - | - | + | + | + | + | - | - | - | - | + | - | na | Chik-CNS, Dengue-Syst |
| 20 | - | - | - | - | - | - | - | + | + | + | - | - | - | - | - | na | Chik-Syst |
| 21 | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | Neg: MCS, VDRL | Chik-Syst |
| 22 | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | na | Zika-CNS |

"+" = positive, "-" = negative, "na" = sample not available or inadequate volume; PCR = polymerase chain reaction; CSF = cerebrospinal fluid; MCS = microscopy, culture and sensitivity; HSV = herpes simplex virus, CMV = cytomegalovirus, VZV = varicella zoster virus, VDRL = venereal disease research laboratory (syphilis), CRAG = cryptococcal antigen, Chik = chikungunya; CNS = virus detected in central nervous system, Syst = virus detected systemically (i.e. outside CNS) only. Zika virus PCR primers used: 1086–1102, 1107–1137.[24] See appendix for antibody levels, IgG results and time between infection and sample collection.

*Preliminary information for this patient has previously been published.

†These patients had PCR evidence of Zika virus infection, with serological evidence of dengue infection potentially secondary to cross-reactivity.

<https://doi.org/10.1371/journal.pntd.0006212.t001>




Fig 2. Venn diagram for 22 patients showing virological evidence of CNS or systemic infection with Zika, chikungunya and/or dengue, and clinical presentation with CNS or peripheral nervous system disease. We distinguish *virological* evidence of CNS or systemic infection (based on PCR/antibody testing) from *clinical* evidence of CNS or peripheral nervous system disease (based on clinical features). Patients in the inner darker circles have

evidence of CNS +/- systemic infection with the respective virus. Those in the outer paler circles have evidence of only systemic infection with the respective virus. Note that patients 1 and 3 had confirmed Zika, +/- dengue; patients 2 and 7 had Zika or dengue or both.

<https://doi.org/10.1371/journal.pntd.0006212.g002>

Fifteen patients presented with CNS disease, including encephalitis and/or myelitis, with or without involvement of the meninges or peripheral nerves. All had a febrile or rash syndrome, many with arthralgia and malaise. The median (range) time delay between this systemic illness and neurological disease was 4 (0–27) days; for these patients with CNS disease, there was no statistically significant difference in prodrome length between those with and without CNS Zika infection.

The eight patients with encephalitis (with or without other CNS disease) had a median (range) Glasgow Coma Scale score of 13.5 (3–15); six were confused, and two had seizures. One patient had a supranuclear gaze palsy; two had facial weakness and four had difficulties with speech or swallowing. The ten patients with myelitis (with or without encephalitis) comprised five with paraparesis (one spastic, two flaccid, and two with normal tone), four with quadraparesis (two spastic, two flaccid) and one with a triparalysis. Seven of these patients had a sensory level, six had urinary retention and three had urinary incontinence. Three patients with flaccid paresis had signs and symptoms compatible with transverse myelitis, namely a sensory level and urinary retention. However, one patient with encephalomyelitis with flaccid areflexic quadraparesis (patient 9) had extensive imaging changes in the anterior of the cord consistent with poliomyelitis-like anterior horn cell damage.

Neurophysiological studies (see below) confirmed the involvement of lower motor neurons for four patients with myelitis: two of those with flaccid paraparesis, one with flaccid quadraparesis, and one with paraparesis and normal tone. The clinical characteristics of the patients with central, peripheral, and mixed nervous system disease are compared in [Table 3](#).

Virology and serology

Zika virus RNA was detected in two CSF, one serum and six urine samples (from eight patients); Zika IgM was detected in 10 CSF and two serum samples (10 patients). Chikungunya virus RNA was detected in 11 CSF, six serum, and three urine samples (14 patients); chikungunya IgM was detected in six CSF and seven serum samples (11 patients). Dengue virus RNA was not found; dengue IgM was found in two CSF and six serum samples (six patients).

As expected, many patients had serum IgG against dengue virus, consistent with prior exposure (appendix). Of the 13 patients with no evidence of recent arbovirus infection, serum Zika virus IgG was detected in four. Anti-GM1, GD1a, GD1b and GQ1b antibodies were found in the serum of patients with both peripheral and central nervous system disease ([Table 2](#)).

Investigations

Ten out of the 22 patients had a CSF pleocytosis ($\geq 5/\mu\text{L}$, all showing predominantly lymphocytes/monocytes) and 15 had a CSF protein above 0.45 g/L. Four patients had a mild thrombocytopenia and seven had a peripheral leucocytosis, but none had leucopenia. Imaging studies are detailed in [Table 2](#), with examples shown in [Fig 3](#). High signal changes were found in the cervical (four patients) and thoracic (two) cord, brainstem (two), cerebellar peduncles (two) and cortex (three); demyelination of the parietal cortex and thalamus was reported in patient 20 and pachymeningeal enhancement in patient 9. Three different neurophysiological patterns were seen in patients with peripheral involvement—acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN) and acute inflammatory demyelinating polyneuropathy (AIDP) (see appendix for original data). AMAN and AMSAN were seen in patients both with and without probable Zika virus infection; AIDP was seen only in one patient with CNS chikungunya virus infection.

Table 2. Individual clinical features of 22 patients presenting with neurological disease associated with Zika, chikungunya and/or dengue virus infection, ordered by date of admission.

| Patient | Virological Diagnosis | Systemic Features | Prodrome Length (days) | Neurological Features | CSF WCC | CSF Protein | Anti-ganglioside Antibody | Neurological Diagnosis (levels of certainty) | Management | Progress and Outcome |
|----------|---|--------------------------------------|------------------------|--|---------|-------------|---------------------------|---|--------------------|--|
| 1 (F/47) | Zika-CNS +/- Dengue-CNS | Rash, arthralgia, malaise WCC 8-0 | 4 | Confusion, dysarthria, drowsiness; paraparesis; GCS 3; CT head—diffuse white matter hypodensities | 10 | 1-11 | GM1 | Encephalitis (I) | Mannitol | ICU; intubated; patient rapidly deteriorated and died |
| 2 (F/59) | Zika-CNS or Dengue-CNS or both, Chik-Syst | Fever, rash, arthralgia WCC 8-1 | 7 | UL and LL paraesthesia; spastic quadraparesis; extensor plantaris; impaired UL and LL LT, PP, Vi, Pr; urinary retention; GCS 15; MRI spine—intramedullary signal abnormality involving cervical and thoracic cord; MRI brain—normal; NP—normal | 4 | 0-36 | GM1, GD1a, GD1b | Myelitis (I) | IVIg; steroids x 2 | Developed pulmonary oedema on IVIG; responded to steroids, mRS 3 at 4 months |
| 3 (M/26) | Zika-CNS +/- Dengue-Syst | Fever | 1 | Confusion; truncal, UL and LL paraesthesia and numbness; spastic hyperreflexic quadraparesis; T5 sensory level; LMN facial nerve and supranuclear gaze palsies; impaired UL and LL LT, PP, Vi, Pr; urinary incontinence; GCS 13; MRI brain and spine—signal abnormality involving cerebellar peduncles, medulla and intramedullary cervical cord | 100 | 1-12 | GM1, GD1a, GD1b | Encephalomyelitis (II) | IVIg; steroids | ICU; intubated; improved, mRS 1 at 4 months |
| 4 (M/34) | Zika/Chik-CNS | Rash | 12 | UL and LL paraesthesia; mild ataxia; bilateral LMN facial nerve palsy; hyperreflexic LL; GCS 15; MRI brain—gadolinium enhancement of bilateral facial nerves; NP—normal | 2 | 0-69 | - | GBS variant (facial diplegia with paraesthesia) | IVIg | Improved, full recovery at 2 months |
| 5 (F/41) | Zika-CNS | Fever, rash, malaise WCC 21-8 | 5 | LL and peri-orbital paraesthesia; normotonic areflexic paraparesis; impaired LL LT, PP, Vi; GCS 15; CT brain—normal | 0 | 2-07 | na | GBS (II) | IVIg | Improved (extent unknown) |
| 6 (F/30) | Chik/Dengue-Syst | Fever, rash, malaise WCC 9-3 | 27 | LL paraesthesia; normoreflexic paraparesis; urinary retention; GCS 15; MRI brain and spine—normal; NP—normal | 0 | 0-21 | - | Myelitis (II) | IVIg; steroids | Improved (extent unknown) |

(Continued)

Table 2. (Continued)

| Patient | Virological Diagnosis | Systemic Features | Prodrome Length (days) | Neurological Features | CSF WCC | CSF Protein | Anti-ganglioside Antibody | Neurological Diagnosis (levels of certainty) | Management | Progress and Outcome |
|-----------|---------------------------------|--|------------------------|--|---------|-------------|---------------------------|---|-------------------------|--|
| 7 (F/66) | Zika-CNS or Dengue-Syst or both | Fever, arthralgia, malaise WCC 7·7 | 13 | UL and LL paraesthesia; flaccid areflexic quadraparesis; bilateral LMN facial nerve palsy; impaired UL and LL LT, PP, Vi; GCS 15; NP—AMSAN | 0 | 0·95 | GD1a | GBS (I) | IVIg | ICU; intubated; improved at 1 week (extent unknown) |
| 8 (M/20) | Chik-CNS | Fever WCC 15·4 | 0 | R UL and LL paraesthesia and tripareisis (L UL spared), hyperreflexic LL; impaired LL LT, PP, Vi, Pr; C6 sensory level; urinary retention; GCS 15; MRI spine—signal abnormality involving cervical and thoracic cord; MRI brain normal; NP—normal | 0 | 0·29 | - | Myelitis (I) | Steroids x 2 | Improved, mRS 2 at 3 weeks |
| 9 (F/80) | Zika/Chik-CNS | Fever, rash, arthralgia, malaise PLT 134 WCC 7·5 | 5 | Headache, confusion; flaccid hyporeflexic quadraparesis; GCS 14; MRI brain and spine—signal abnormality involving anterior medulla, anterior cervical and thoracic cord, temporal lobes, amygdala, small area adjacent to temporal horn of L lateral ventricle, pachymeningeal enhancement | 117 | 1·74 | na | Encephalomyelitis (I,I) with subclinical meningitis | IVIg | ICU; developed sacral osteomyelitis; improved, mRS 4 at 2 months |
| 10 (M/38) | Zika-CNS | Fever, rash, malaise PLT 220 WCC 14·0 | 10 | LL paraesthesia; flaccid areflexic quadraparesis; L LMN facial nerve palsy; impaired LL Pr; GCS 15 | 1 | 1·72 | - | GBS (II) | IVIg; antivirals | ICU; intubated, ventilator-associated pneumonia; improved (extent unknown) |
| 11 (M/76) | Chik-CNS | Rash, arthralgia PLT 254 WCC 13·0 | 0 | 2 seizures; confusion, dysarthria, headache, neck stiffness; spastic paraparesis; extensor plantars, palmomental reflex; LL neuropathic pain; T2-3 sensory level; urinary incontinence; GCS 14 | 80 | 1·45 | GD1a | Meningoencephalomyelitis (III,I,III) | Antivirals; antibiotics | Unknown outcome |

(Continued)

Table 2. (Continued)

| Patient | Virological Diagnosis | Systemic Features | Prodrome Length (days) | Neurological Features | CSF WCC | CSF Protein | Anti-ganglioside Antibody | Neurological Diagnosis (levels of certainty) | Management | Progress and Outcome |
|-----------|-----------------------|---|------------------------|---|---------|-------------|---------------------------|--|--|--|
| 12 (M/63) | Chik-CNS | Fever, rash, arthralgia, malaise | 2 | LL paraesthesia; flaccid areflexic paraparesis; T4 sensory level; urinary retention; fell with intracranial injury; GCS 15 on admission, 12 after fall; CT brain normal, MRI brain and spine normal; NP—AMSAN | 0 | 0.92 | - | Myeloradiculitis (II) | IVIG | ICU, intubated (after fall and head injury); no improvement; mRS 5 at 2 months |
| | | PLT 116 | | | | | | | | |
| | | WCC 6.5 | | | | | | | | |
| 13 (F/51) | Chik-CNS | Fever, arthralgia, malaise | 6 | Confusion, 1 x seizure, drowsiness, dysarthria; GCS 3; CT head normal | 11 | 0.45 | GQ1b | Encephalitis (I) | Antivirals | Improved, full recovery at 2 months |
| 14 (M/45) | Chik-CNS | Fever, arthralgia, malaise, diarrhoea | 29 | UL and LL paraesthesia; flaccid areflexic quadraparesis; impaired UL and LL LT, PP; GCS 15 | 0 | 0.75 | na | GBS (II) | IVIG | ICU; improved mRS 3 |
| | | PLT 203 | | | | | | | | |
| | | WCC 8.7 | | | | | | | | |
| 15 (M/84) | Chik-CNS | Fever, rash, arthralgia, malaise, diarrhoea | 4 | Confusion, impaired speech and swallow; flaccid hyporeflexic quadraparesis; myalgia; GCS 8; MRI brain—focal areas of hyperintensity likely related to microangiopathy; NP— inflammatory myopathy | 42 | 1.11 | na | Encephalitis (I), Myositis | IVIG; antivirals; antibiotics; antifungals | Ventilator-associated pneumonia; no improvement, mRS 5 at 6 weeks |
| | | PLT 80 | | | | | | | | |
| | | WCC 16.3 | | | | | | | | |
| 16 (M/65) | Zika/Chik-CNS | Fever, rash, arthralgia, malaise | 0 | LL paraesthesia; flaccid areflexic paraparesis; T11 sensory level; impaired LL sensation LT, PP, Vi, Pr; urinary retention; GCS 15; MRI brain and spine normal; NP—AMSAN | 10 | 1.08 | na | Myeloradiculitis (I) | IVIG; steroids | No improvement at 3 weeks |
| | | PLT 130 | | | | | | | | |
| | | WCC 9.9 | | | | | | | | |
| 17 (F/19) | Zika/Chik-Syst | Rash | 41 | UL and LL paraesthesia; quadraparesis, hyporeflexic LL; GCS 15; CT brain normal; NP—AMAN; patient 19 weeks pregnant at admission, foetus diagnosed with Dandy-Walker syndrome | 2 | 0.23 | - | GBS (II) | IVIG | No improvement at 3 weeks |
| | | PLT 537 | | | | | | | | |
| | | WCC 9.0 | | | | | | | | |
| 18 (F/56) | Chik-CNS, Zika-Syst | Fever, rash, malaise | 4 | LL paraesthesia; flaccid areflexic quadraparesis; impaired UL & LL LT, PP, Vi, Pr; C7 sensory level; urinary retention; GCS 15; MRI brain and spine normal; NP—AMSAN | 0 | 0.71 | na | Myeloradiculitis (II) | IVIG; steroids | No improvement, mRS 5 at 1 month |
| | | PLT 340 | | | | | | | | |
| | | WCC 15.0 | | | | | | | | |

(Continued)

Table 2. (Continued)

| Patient | Virological Diagnosis | Systemic Features | Prodrome Length (days) | Neurological Features | CSF WCC | CSF Protein | Anti-ganglioside Antibody | Neurological Diagnosis (levels of certainty) | Management | Progress and Outcome |
|-----------|-----------------------|---|------------------------|---|---------|-------------|---------------------------|--|----------------|--|
| 19 (M/62) | Chik-CNS, Dengue-Syst | Fever, rash PLT 680 WCC 18.8 | 8 | LL paraesthesia; normotonic hyperreflexic paraplegia; extensor plantars; impaired LL Vi; T6-8 sensory level; urinary incontinence; GCS 15; CT brain normal, MRI brain and spine normal; NP—AIDP | 16 | 1.09 | - | Myeloradiculitis (I) | IVIG; steroids | Improved, mRS 2 at 1 month |
| 20 (M/17) | Chik-Syst | Fever, rash PLT 362 WCC 6.3 | 16 | L sided numbness (LL, UL, truncal); L hemiparesis; L UMN facial nerve palsy; headache; impaired L sided UL & LL LT, PP; GCS 15; MRI brain—demyelinating lesions R parietal lobe & thalamus consistent with ADEM | na | 0.44 | na | ADEM | IVIG; steroids | Improved, mRS 2 at 3 weeks |
| 21 (F/67) | Chik-Syst | Fever, arthralgia PLT 397 WCC 8.9 | 7 | Flaccid areflexic quadraparesis; dysphagia; palatal weakness; dyspnoea; impaired UL & LL Pr, LL Vi; GCS 15; CT brain normal; NP—AMSAN | 10 | 0.71 | - | GBS (I) | IVIG x 2 | ICU; intubated; no improvement, mRS 5 at 2 weeks |
| 22 (F/52) | Zika-CNS | Fever PLT 412 WCC 10.2 | 0 | LL and R facial numbness, impaired co-ordination; headache, diplopia; GCS 15; MRI brain—signal abnormality involving frontal and parietal lobes, pons and right cerebellar peduncle | 6 | 0.37 | GD1a | Encephalitis* | Steroids | Improved, mRS 0 at 2 months |

Prodrome length = interval between onset of infection and neurological illness; Chik = chikungunya; CNS = virus detected in central nervous system, Syst = virus detected systemically (i.e. outside CNS) only; PLT = platelet count $\times 10^9/L$, WCC = white cell count (systemic $\times 10^9/L$, CSF μL); L = left, R = right, LL = lower limb, UL = upper limb, CSF = cerebrospinal fluid, LMN = lower motor neuron, UMN = upper motor neuron, LT = light touch, PP = pinprick, Vi = vibration, Pr = proprioception, GCS = Glasgow coma scale; MRI = magnetic resonance imaging, CT = computed tomography, NP = neurophysiology; AMSAN = acute motor and sensory axonal neuropathy; AMAN = acute motor axonal neuropathy; AIDP = acute inflammatory demyelinating polyneuropathy; GBS = Guillain-Barré syndrome, ADEM = acute disseminated encephalomyelitis; IVIG = intravenous immunoglobulin; ICU = intensive care unit admission, mRS = modified Rankin Scale; "na" = not available. For neurological diagnoses the levels of diagnostic certainty are indicated I-III (highest to lowest), as per the Brighton and other criteria (appendix). The time post-onset of neurological symptoms is given for outcomes, where known.

*Although the GCS score was 15, the clinical features and imaging indicated focal encephalitis.

<https://doi.org/10.1371/journal.pntd.0006212.t002>

Outcome

Eight (36%; four with confirmed Zika) of the 22 patients required admission to an intensive care unit; six (27%) needed intubation (including half the patients with GBS). Ten patients were treated with intravenous immunoglobulin, two with corticosteroids, and seven with

Box 1 Clinical presentation of encephalomyelitis (with subclinical meningitis) associated with Zika and chikungunya virus infections (patient 9)

The initial symptoms of arboviral infection included fever (82% of the patients), rash (68%), malaise (55%) and arthralgia (50%). Two patients had diarrhoea in the month preceding their neurological illness (Table 2); no patient reported a preceding lower respiratory tract infection or conjunctivitis. Five (patients 11, 13, 15, 16, 22) reported previous dengue. One (patient 22) reported prior vaccination against yellow fever. The median (range) time between infective symptoms and onset of neurological disease was 6.5 (0–41) days. Patients presented with a range of neurological syndromes affecting the CNS, peripheral nervous system, or both, as detailed in Table 2.

both; four with encephalitis received aciclovir as presumptive treatment for herpes simplex virus encephalitis. Four patients developed hospital acquired infections, including ventilator-associated pneumonia and sacral osteomyelitis secondary to immobility. Fourteen (of 21 with outcome data, 67%; six with confirmed Zika) patients improved; one with evidence of Zika +/- dengue infection of the CNS deteriorated rapidly and died.

Discussion

With 84 countries or territories now affected by Zika virus,[29] increasing reports of associated neurological disease other than GBS,[10–13, 15, 16] and growing concern about coinfections with other arboviruses,[30] there is an urgent need to determine the full spectrum of Zika's neurological complications and its relationship with other arboviruses. In our study, which begins to address these questions, over half of the patients with Zika virus infection had presentations other than GBS, suggesting that these complications may be more important than recognised previously. Patients had involvement of the meninges, brain parenchyma, spinal cord, and peripheral nerves in various combinations, as evidenced by the clinical features, imaging and neurophysiological findings, and as has been described for other flaviviruses.[9]

Four patients with evidence of Zika virus infection also had CNS infection with chikungunya virus. Ten further patients negative for Zika tested positive for chikungunya. In South America, reports of neurological disease associated with chikungunya virus are scarce, which may reflect a lack of awareness among clinicians about the potential to affect the nervous system, or the relatively recent arrival of the virus. Interestingly, in one patient (patient 17) virus was detected 30 days after the onset of neurological disease, suggesting a persistent infection or a late coincidental infection. In our study of patients from Rio de Janeiro, chikungunya virus was as important a cause of neurological disease as Zika virus. Its importance in other settings where Zika virus is assumed to be the cause of febrile illness, with or without neurological disease, needs to be assessed urgently.

We are only now beginning to understand the full spectrum of neurological syndromes associated with both Zika and chikungunya infections. For example, patient 19 showed clinical signs of myeloradiculitis and had neurophysiological evidence of AIDP, which is consistent with simultaneous diagnoses of both myelopathy and a form of GBS. Another patient (15) had an unusual combination of encephalitis, cerebral microangiopathy demonstrated on MRI and inflammatory myopathy based on neurophysiological studies. We saw evidence of extensive

Table 3. Clinical characteristics of 22 patients presenting with neurological disease associated with Zika, chikungunya and/or dengue virus infection.

| | n (%) or median (IQR) | | | |
|--|-----------------------|----------------------|---------------------|---------------------------|
| | All patients (n = 22) | CNS disease (n = 11) | PNS disease (n = 7) | CNS & PNS disease (n = 4) |
| Age (years) | 51.5 (35–64.5) | 51 (28–67.5) | 41 (35–55.5) | 62.5 (60.5–63.5) |
| Males | 11 (50%) | 5 (45%) | 3 (43%) | 3 (75%) |
| Previous yellow fever vaccination (of 12 patients) | 1 (8%) | 1 of 4 (25%) | 0 of 4 (0%) | 0 (0%) |
| Previous dengue (of 20 patients) | 5 (25%) | 4 (36%) | 0 of 5 (0%) | 1 of 3 (33%) |
| Co-morbidity (of 20 patients) | 10 (50%) | 5 (45%) | 2 of 6 (33%) | 3 of 3 (100%) |
| Diabetes mellitus (type II) | 2 (10%) | 2 (18%) | 0 of 6 (0%) | 0 of 3 (0%) |
| Stroke | 2 (10%) | 0 (0%) | 2 of 6 (33%) | 0 of 3 (0%) |
| Hypertension | 6 (30%) | 3 (27%) | 0 of 6 (0%) | 3 of 3 (100%) |
| Hypercholesterolaemia | 2 (10%) | 1 (9%) | 1 of 6 (17%) | 0 of 3 (0%) |
| Cancer | 2 (10%) | 1 (9%) | 0 of 6 (0%) | 1 of 3 (33%) |
| Asthma | 1 (5%) | 1 (9%) | 0 of 6 (0%) | 0 of 3 (0%) |
| Cardiac disease | 1 (5%) | 0 (0%) | 1 of 6 (17%) | 0 of 3 (0%) |
| Neurological disease (Tourette's syndrome) | 1 (5%) | 1 (9%) | 0 of 6 (0%) | 0 of 3 (0%) |
| Systemic features | | | | |
| Fever | 18 (82%) | 9 (82%) | 5 (71%) | 4 (100%) |
| Rash | 15 (68%) | 7 (64%) | 4 (57%) | 4 (100%) |
| Arthralgia | 11 (50%) | 6 (55%) | 3 (43%) | 2 (50%) |
| Malaise | 12 (55%) | 5 (45%) | 4 (57%) | 3 (75%) |
| Diarrhoea | 2 (9%) | 1 (9%) | 1 (14%) | 0 (0%) |
| Prodrome length (days) | 5.5 (2.5–11.5) | 4 (0.5–6.5) | 12 (8.5–21) | 3 (1.5–5) |
| Neurological symptoms | | | | |
| Weakness | 19 (86%) | 9 (82%) | 6 (86%) | 4 (100%) |
| Sensory disturbance | 17 (77%) | 7 (64%) | 6 (86%) | 4 (100%) |
| Neurological examination (of 21 patients) | | | | |
| Cranial nerve involvement | 6 (29%) | 2 of 10 (20%) | 4 (57%) | 0 (0%) |
| Sensory level | 8 (38%) | 4 of 10 (40%) | 0 (0%) | 4 (100%) |
| GCS<15 on admission | 8 (38%) | 6 of 10 (60%) | 1 (14%) | 1 (25%) |
| Diminished or absent reflexes | 11 (52%) | 2 of 10 (20%) | 6 (86%) | 3 (75%) |
| Brisk reflexes | 6 (29%) | 4 of 10 (40%) | 1 (14%) | 1 (25%) |
| Lumbar puncture results | | | | |
| CSF white cell count (of 21 patients) | 4 (0–11) | 10.5 (4.5–70.5) | 1 (0–2) | 5 (0–11.5) |
| CSF protein | 83.5 (44.25–111) | 45 (36.4–111.5) | 75 (70–133.2) | 100 (86.8–108.3) |
| Treatment | | | | |
| IVIg | 17 (77%) | 6 (55%) | 7 (100%) | 4 (100%) |
| Steroids | 9 (41%) | 6 (55%) | 0 (0%) | 3 (75%) |
| Outcome | | | | |
| Responded to treatment (of 21 patients) | 14 (67%) | 7 of 10 (70%) | 5 (71%) | 2 (50%) |
| Admitted to ICU | 8 (36%) | 3 (27%) | 4 (57%) | 1 (25%) |
| Intubated | 6 of 21 (29%) | 2 of 10 (20%) | 3 (43%) | 1 (25%) |
| Died | 1 (5%) | 1 (9%) | 0 (0%) | 0 (0%) |

CNS = central nervous system; PNS = peripheral nervous system. For certain parameters we did not have data for all patients; the number of patients for whom data was available is indicated in brackets.

<https://doi.org/10.1371/journal.pntd.0006212.t003>

intramedullary myelitis in some patients, and anterior myelitis in another (e.g. patients 2 and 9 respectively, Fig 3); the latter is consistent with anterior horn cell disease seen in other




Fig 3. Central nervous system (CNS) imaging abnormalities in patients with evidence of Zika, chikungunya and/or dengue virus infection. A: Encephalomyelitis in a patient with CNS Zika and systemic dengue infection (patient 3). Fluid attenuation inversion recovery [FLAIR] signal abnormality involving the middle cerebellar peduncles, more marked on the right (axial scan). B: Acute disseminated encephalomyelitis in a patient with systemic chikungunya infection (patient 20). Confluent areas of T2 signal abnormality suggesting neuroinflammation consistent with demyelination (coronal scan). C, D, E: Encephalomyelitis with subclinical meningitis in a patient with CNS Zika + chikungunya infection (patient 9). FLAIR signal abnormality involving the medial temporal lobes, amygdala, and a small area of abnormality adjacent to the temporal horn of the left lateral ventricle (C, axial scan). High signal intensity on T2-weighted images in the anterior medulla, and anterior cervical and thoracic cord (D and E, sagittal scans). F, G, H: Myelitis in a patient with CNS Zika + dengue and systemic chikungunya infection (patient 2). Extensive intramedullary signal abnormality of the cervical cord, without evidence of contrast enhancement (F, sagittal T2-weighted scan; G, sagittal T1-weighted scan with gadolinium; H, axial T2-weighted scan). I, J: Facial diplegia with paraesthesia in patient with CNS Zika + chikungunya infection (patient 4). Bilateral facial nerve enhancement on T2-weighted images with gadolinium (axial scan).

<https://doi.org/10.1371/journal.pntd.0006212.g003>

flavivirus infections.[31] In the French Polynesian study, neurophysiological investigations showed that all Zika patients with GBS had the AMAN subtype;[4] whereas in the Colombian study, almost all had AIDP.[5] In our study we additionally found AMSAN, confirming involvement of the sensory axons in Zika virus-associated GBS. One patient with AMSAN had anti-GD1a antibodies, which is more normally associated with AMAN. Anti-GD1a antibodies were also detected in Zika and chikungunya patients with central nervous system disease (Table 2). We also found anti-GM1, anti-GD1b, and anti-GQ1b antibodies in patients with central nervous system disease. Anti-GM1 antibodies are associated with AMAN, anti-GD1b with sensory ataxic neuropathy, and anti-GQ1b with Miller Fisher syndrome and Bickerstaff's

brainstem encephalitis.[32] The significance of detecting these antibodies in patients with encephalitis and myelitis is not certain.

Although in our study six patients had evidence of recent systemic dengue virus infection, five of them also had evidence of CNS infection with a different virus, suggesting dengue on its own was less likely to be the cause of the neurological disease. We might have expected to see more dengue-associated neurology, given that the virus is circulating widely in Rio de Janeiro [33] and is a well-recognised cause of neurological disease.[22] Whether this in some way reflects the fact that it has been circulating for over 30 years in this city,[34] but Zika and chikungunya viruses have been newly introduced, is not known. Alternatively, this may be due to differing neurovirulence of the three viruses.

For dengue, secondary infection is a risk factor for more severe systemic dengue disease, a phenomenon thought to be mediated by antibody-dependent enhancement.[35] Interestingly, in a recent *in vitro* study, plasma immune to dengue virus induced potent antibody-dependent enhancement of Zika virus.[36] In our cases, all serum samples were positive for dengue IgG antibody, indicating prior flavivirus exposure, a pattern also seen in 86% of tested patients in the Colombian report on GBS.[5] Larger prospective studies are needed to investigate whether such dengue exposure is a risk factor for developing neurological disease after Zika virus infection.

Combined infection of arboviruses has not been well described in those with neurological presentations. In our patients with evidence of dual infections, whether the neurological disease was caused by one arbovirus or the other, or by a combination of the two is unclear. The fact that so many of our patients had evidence of dual infection may indicate that combined infections are responsible for severe disease, as we have seen in other settings.[37]

Flaviviruses can cause neurological disease by attacking the nervous system directly or indirectly via immune-mediated processes; the latter tend to occur some time after the acute infection, making virological diagnosis especially challenging. Detection of virus in the CSF is usually taken as the strongest evidence of causality, but it has often cleared by the time patients present, making us reliant on detection of virus systemically or demonstration of CSF or serum IgM antibody. For both Zika and chikungunya, whether testing urine for RNA increases the window of detection compared to serum is debated.[38–40] In our series, six patients (two with CNS disease) with no virus in the CSF or serum had virus detected in the urine (five Zika, one chikungunya), underscoring the value of testing this sample.

Our results must be interpreted in the context of the study's limitations. First, cross-reactivity between flaviviruses makes distinguishing Zika from dengue by serological tests challenging.[4, 8] In four patients (two of whom were positive for Zika by PCR), we found elevated IgM antibody to both dengue and Zika, which may represent cross reactivity. Even in cases where CSF IgM was detected for Zika but not dengue virus, given the unknown specificity and sensitivity of the available flavivirus serological tests, caution must be applied. Newer assays in development and plaque reduction neutralization testing will help in the future. Differentiating infections clinically was also difficult; conjunctivitis is commonly seen in Zika[1] and not often reported for dengue or chikungunya, but we did not find conjunctivitis or any other clinical features that could distinguish the infections in our series. We did not look for West Nile virus because it was not circulating in Rio de Janeiro at the time of our study, but this may be important in other settings. Second, given the retrospective nature of the study, we did not have all CSF, serum and urine samples for each patient, thus potentially under-diagnosing arboviral infections in the cohort; in addition, the timing of sample collection was not standardised. Third, we only studied patients who had symptoms consistent with Zika infection. Whether Zika virus can cause neurological disease in patients with no febrile illness will need to be addressed in future studies. Fourth, our study included a relatively small number of

patients, thus the spectrum of neurology and role of chikungunya described may be even more extensive.

In summary, our study adds to the growing body of evidence arguing for a wide spectrum of neurological disease associated with Zika virus infection, including central nervous system disease. Some patients in whom a Zika virus-associated neurological disorder was suspected were actually infected with chikungunya virus, and many were infected with more than one arbovirus. The Zika public health emergency was recently declared over, recognising that the virus is here to stay and a sustained technical and research response is needed.[7] To understand fully the disease burden of Zika virus, clinicians and public health officials need to look beyond GBS, and also to investigate for other arboviruses that may cause similar neurological disease, particularly chikungunya.

Supporting information

S1 Checklist. STROBE checklist.

(DOC)

S1 Appendix. Additional information including hospital names, diagnostic criteria, diagnoses of patients without evidence of arbovirus infection, neurophysiology data, immunological assays and days between infection and sample collection, and statistical analyses.

(DOCX)

Acknowledgments

We would like to thank staff at the Fiocruz Flavivirus Reference Laboratory, in particular Angelica Mares-Guia, Ronaldo Lopes, Aline da Silva Santos, Cintia Damasceno, Maria Celeste Torres, Flavia Levy, Simone Sampaio, Eliane Araujo, Sheila Cheles, Marcos Cesar Lima de Mendonça and Marilda Siqueira for their ceaseless support.

Author Contributions

Conceptualization: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Mark Ellul, Marcus Tullius Texeira da Silva, Lance Turtle, Patricia Carvalho de Sequeira, David W. Brown, Michael J. Griffiths, Ana Maria Bispo de Filippis, Tom Solomon.

Data curation: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Marcus Tullius Texeira da Silva, Marcia Rodrigues Jardim, Luciana Pamplona, Gabriel Amorelli Medeiros da Silva, Marcus Vinicius Adriano, Patricia Brasil, Carolina Cardoso Dos Santos.

Formal analysis: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Anna Rosala-Hallas, Marcia Rodrigues Jardim, Girvan Burnside, Maneesh Bhojak, Radhika Manohar, David W. Brown, Ana Maria Bispo de Filippis, Tom Solomon.

Funding acquisition: Tom Solomon.

Investigation: Ravi Mehta, Cristiane Nascimento Soares, Marcus Tullius Texeira da Silva, Marcia Rodrigues Jardim, Luciana Pamplona, Gabriel Amorelli Medeiros da Silva, Marcus Vinicius Adriano, Patricia Brasil, David W. Brown.

Methodology: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Mark Ellul, Lance Turtle, David W. Brown, Michael J. Griffiths, Ana Maria Bispo de Filippis, Tom Solomon.

Project administration: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Rita Maria Ribeiro Nogueira, Patricia Carvalho de Sequeira, David W. Brown, Tom Solomon.

Resources: Ravi Mehta, Cristiane Nascimento Soares, Marcus Tullius Texeira da Silva, Marcia Rodrigues Jardim, Luciana Pamplona, Patricia Carvalho de Sequeira, David W. Brown, Tom Solomon.

Supervision: Mark Ellul, David W. Brown, Michael J. Griffiths, Ana Maria Bispo de Filippis, Tom Solomon.

Writing – original draft: Ravi Mehta, Raquel Medialdea-Carrera, Tom Solomon.

Writing – review & editing: Ravi Mehta, Cristiane Nascimento Soares, Raquel Medialdea-Carrera, Mark Ellul, Rita Maria Ribeiro Nogueira, Lance Turtle, David W. Brown, Michael J. Griffiths, Ana Maria Bispo de Filippis, Tom Solomon.

References

- Musso D, Gubler DJ. Zika Virus. *Clin Microbiol Rev.* 2016; 29(3):487–524. <https://doi.org/10.1128/CMR.00072-15> PMID: 27029595
- Brazilian Ministry of Health. Protocolo de vigilância e resposta à ocorrência de microcefalia 2016 [Available from: <http://portalsaude.saude.gov.br/images/pdf/2016/janeiro/22/microcefalia-protocolo-de-vigilancia-e-resposta-v1-3-22jan2016.pdf>].
- Arias A, Torres-Tobar L, Hernandez G, Paipilla D, Palacios E, Torres Y, et al. Guillain-Barre syndrome in patients with a recent history of Zika in Cucuta, Colombia: A descriptive case series of 19 patients from December 2015 to March 2016. *J Crit Care.* 2017; 37:19–23. <https://doi.org/10.1016/j.jcrc.2016.08.016> PMID: 27610587
- Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet.* 2016; 387(10027):1531–9. [https://doi.org/10.1016/S0140-6736\(16\)00562-6](https://doi.org/10.1016/S0140-6736(16)00562-6) PMID: 26948433
- Parra B, Lizarazo J, Jimenez-Arango JA, Zea-Vera AF, Gonzalez-Manrique G, Vargas J, et al. Guillain-Barre Syndrome Associated with Zika Virus Infection in Colombia. *N Engl J Med.* 2016; 375:1513–23. <https://doi.org/10.1056/NEJMoa1605564> PMID: 27705091
- Malta JMAS, Vargas A, Leite PLe, Percio J, Coelho GE, Ferraro AHA, et al. Síndrome de Guillain-Barré e outras manifestações neurológicas possivelmente relacionadas à infecção pelo vírus Zika em municípios da Bahia, 2015. *Epidemiologia e Serviços de Saúde.* 2017; 26:9–18. <https://doi.org/10.5123/S1679-49742017000100002> PMID: 28226004
- World Health Organisation. Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus 2016 [Available from: <http://www.who.int/mediacentre/news/statements/2016/zika-fifth-ec/en/>].
- Smith DW, Mackenzie J. Zika virus and Guillain-Barre syndrome: another viral cause to add to the list. *Lancet.* 2016; 387(10027):1486–8. [https://doi.org/10.1016/S0140-6736\(16\)00564-X](https://doi.org/10.1016/S0140-6736(16)00564-X) PMID: 26948432
- Solomon T, Kneen R, Dung NM, Khanh VC, Thuy TT, Ha DQ, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. *Lancet.* 1998; 351(9109):1094–7. [https://doi.org/10.1016/S0140-6736\(97\)07509-0](https://doi.org/10.1016/S0140-6736(97)07509-0) PMID: 9660579
- Mecharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, et al. Acute myelitis due to Zika virus infection. *Lancet.* 2016; 387(10026):1481. [https://doi.org/10.1016/S0140-6736\(16\)00644-9](https://doi.org/10.1016/S0140-6736(16)00644-9) PMID: 26946926
- Roze B, Najjioullah F, Signate A, Apetse K, Brouste Y, Gourgoudou S, et al. Zika virus detection in cerebrospinal fluid from two patients with encephalopathy, Martinique, February 2016. *Euro Surveill.* 2016; 21(16).
- Soares CN, Brasil P, Carrera RM, Sequeira P, de Filippis AB, Borges VA, et al. Fatal encephalitis associated with Zika virus infection in an adult. *J Clin Virol.* 2016; 83:63–5. <https://doi.org/10.1016/j.jcv.2016.08.297> PMID: 27598870
- Carteaux G, Maquart M, Bedet A, Contou D, Brugieres P, Fourati S, et al. Zika Virus Associated with Meningoencephalitis. *N Engl J Med.* 2016; 374(16):1595–6. <https://doi.org/10.1056/NEJMc1602964> PMID: 26958738

14. Niemeyer B, Niemeyer R, Borges R, Marchiori E. Acute Disseminated Encephalomyelitis Following Zika Virus Infection. *European neurology*. 2017; 77(1–2):45–6. <https://doi.org/10.1159/000453396> PMID: 27894121
15. Kassavetis P, Joseph JM, Francois R, Perloff MD, Berkowitz AL. Zika virus-associated Guillain-Barre syndrome variant in Haiti. *Neurology*. 2016; 87(3):336–7. <https://doi.org/10.1212/WNL.0000000000002759> PMID: 27164708
16. Molko N, Simon O, Guyon D, Biron A, Dupont-Rouzeyrol M, Gourinat AC. Zika virus infection and myasthenia gravis: Report of 2 cases. *Neurology*. 2017.
17. Bureau de la Veille Sanitaire de la Direction de la Santé Publique. Surveillance de la dengue et du zika en Polynésie française 2014 [Available from: <http://www.hygiene-publique.gov.pf/spip.php?article120>].
18. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. *N Engl J Med*. 2015; 372(13):1231–9. <https://doi.org/10.1056/NEJMra1406035> PMID: 25806915
19. Pan American Health Organisation. Chikungunya: Statistic Data 2016 [Available from: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=343&Itemid=40931].
20. Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. *Rev Med Virol*. 2009; 19(3):121–9. <https://doi.org/10.1002/rmv.606> PMID: 19274635
21. Martins HAL, Bernardino SN, Ribas KH, Santos CC, Antunes T, et al. Outbreak of Neuro-Chikungunya in Northeastern Brazil. *Journal of Neuroinfectious Diseases*. 2016; 7(2).
22. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection. *Lancet*. 2000; 355(9209):1053–9. [https://doi.org/10.1016/S0140-6736\(00\)02036-5](https://doi.org/10.1016/S0140-6736(00)02036-5) PMID: 10744091
23. World Health Organisation. Laboratory testing for Zika virus infection—interim guidance 2016 [Available from: <http://www.who.int/csr/resources/publications/zika/laboratory-testing/en/>].
24. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis*. 2008; 14(8):1232–9. <https://doi.org/10.3201/eid1408.080287> PMID: 18680646
25. Steinhagen K, Probst C, Radzimski C, Schmidt-Chanasit J, Emmerich P, van Esbroeck M, et al. Sero-diagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. *Euro Surveill*. 2016; 21(50).
26. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M. High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses. *Euro Surveill*. 2016; 21(16).
27. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparco-Goffart I. Evaluation of commercially available serologic diagnostic tests for chikungunya virus. *Emerg Infect Dis*. 2014; 20(12):2129–32. <https://doi.org/10.3201/eid2012.141269> PMID: 25418184
28. Centers for Disease Control and Prevention. Zika MAC-ELISA Instructions for Use 2016 [Available from: <http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM488044.pdf>].
29. World Health Organisation. Situation Report—Zika Virus, Microcephaly, Guillain-Barré Syndrome 2016 [Available from: <http://www.who.int/emergencies/zika-virus/situation-report/en/>].
30. Acevedo N, Waggoner J, Rodriguez M, Rivera L, Landivar J, Pinsky B, et al. Zika Virus, Chikungunya Virus, and Dengue Virus in Cerebrospinal Fluid from Adults with Neurological Manifestations, Guayaquil, Ecuador. *Frontiers in microbiology*. 2017; 8:42. <https://doi.org/10.3389/fmicb.2017.00042> PMID: 28174559
31. Solomon T. Flavivirus encephalitis. *N Engl J Med*. 2004; 351(4):370–8. <https://doi.org/10.1056/NEJMra030476> PMID: 15269317
32. Wakerley BR, Uncini A, Yuki N, Group GBSC, Group GBSC. Guillain-Barre and Miller Fisher syndromes—new diagnostic classification. *Nature reviews Neurology*. 2014; 10(9):537–44. <https://doi.org/10.1038/nrneurol.2014.138> PMID: 25072194
33. Brazilian Ministry of Health. Epidemiological Bulletin 2017 [Available from: <http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/197-secretaria-svs/11955-boletins-epidemiologicos-arquivos>].
34. Teixeira MG, Costa Mda C, Barreto F, Barreto ML. Dengue: twenty-five years since reemergence in Brazil. *Cad Saude Publica*. 2009; 25 Suppl 1:S7–18.
35. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. *Arch Virol*. 2013; 158(7):1445–59. <https://doi.org/10.1007/s00705-013-1645-3> PMID: 23471635

36. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. *Nat Immunol*. 2016; 17(9):1102–8. <https://doi.org/10.1038/ni.3515> PMID: 27339099
37. Mallewa M, Vallely P, Faragher B, Banda D, Klapper P, Mukaka M, et al. Viral CNS infections in children from a malaria-endemic area of Malawi: a prospective cohort study. *Lancet Glob Health*. 2013; 1(3): e153–60. [https://doi.org/10.1016/S2214-109X\(13\)70060-3](https://doi.org/10.1016/S2214-109X(13)70060-3) PMID: 24748325
38. Gourinat AC, O'Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. *Emerg Infect Dis*. 2014; 21(1):84–6.
39. Paz-Bailey G, Rosenberg ES, Doyle K, Munoz-Jordan J, Santiago GA, Klein L, et al. Persistence of Zika Virus in Body Fluids—Preliminary Report. *N Engl J Med*. 2017.
40. Musso D, Teissier A, Rouault E, Teururai S, de Pina JJ, Nhan TX. Detection of chikungunya virus in saliva and urine. *Virology journal*. 2016; 13:102. <https://doi.org/10.1186/s12985-016-0556-9> PMID: 27306056